Documents

A list of downloadable documents created during development.

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: equality impact assessment - guidance development

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: final appraisal determination

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appraisal consultation 2

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appraisal consultation

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix B - final scope

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix B - draft scope for consultation (pre-referral) May 2011

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix C - final matrix

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix C - provisional matrix (pre-referral) May 2011

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix D - NICE's response to consultee and commentator comments on the draft scope and matrix

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: equality impact assessment